Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Uveal Melanoma 1Osteosarcoma 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NIH × CR011-vcMMAE × Clear all
NCT02487979 2022-01-18

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 15 charts
Sarcoma

Osteosarcoma

NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 12 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡